Zobrazeno 1 - 10
of 13
pro vyhledávání: '"D J, Cushing"'
Autor:
A H, Gradman, A, Lewin, B T, Bowling, M, Tonkon, P C, Deedwania, A E, Kezer, J D, Hardison, D J, Cushing, E L, Michelson
Publikováno v:
Heart disease (Hagerstown, Md.). 1(2)
The antihypertensive efficacy and tolerability of the novel angiotensin-II (A-II) receptor blocker candesartan cilexetil and the prototype A-II receptor blocker, losartan, were compared in an 8-week, multicenter, double-blind, randomized, parallel-gr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::758fd8708f0c4f0652dda6b10eabec58
https://pubmed.ncbi.nlm.nih.gov/11720604
https://pubmed.ncbi.nlm.nih.gov/11720604
Autor:
S, Oparil, J H, Levine, C A, Zuschke, A H, Gradman, E, Ripley, D W, Jones, J D, Hardison, D J, Cushing, R, Prasad, E L, Michelson
Publikováno v:
The American journal of cardiology. 84(3)
The efficacy, tolerability, and safety of the potent angiotensin II receptor blocker candesartan cilexetil were evaluated in 217 adult patients (68% men, 41% black) with severe systemic hypertension on background therapy with hydrochlorothiazide (HCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::39750fa7cc3ddf9aa826095a67ffb285
https://pubmed.ncbi.nlm.nih.gov/10496437
https://pubmed.ncbi.nlm.nih.gov/10496437
Autor:
C A, Zuschke, I, Keys, M A, Munger, A A, Carr, G N, Marinides, T L, Flanagan, D J, Cushing, J L, Hayes, E L, Michelson
Publikováno v:
Clinical therapeutics. 21(3)
This randomized, double-masked, placebo-controlled, forced-titration, parallel-arm study was designed to compare the blood pressure (BP)-lowering effect of candesartan cilexetil, a potent antagonist of the angiotensin II receptor subtype AT1, adminis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b0e11e828b19a6a6e8778aed4c1b3d22
https://pubmed.ncbi.nlm.nih.gov/10321416
https://pubmed.ncbi.nlm.nih.gov/10321416
Autor:
M, Reif, W B, White, T C, Fagan, S, Oparil, T L, Flanagan, D T, Edwards, D J, Cushing, E L, Michelson
Publikováno v:
The American journal of cardiology. 82(8)
The objectives of this double-blind, multicenter, randomized, parallel-arm, placebo-controlled study were to evaluate the dose-related efficacy, tolerability, and safety of candesartan cilexetil, a potent, AT1 selective, long-acting angiotensin II re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7d606abe587760bd1c3b3f70a1bf2e62
https://pubmed.ncbi.nlm.nih.gov/9794352
https://pubmed.ncbi.nlm.nih.gov/9794352
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 277(3)
The canine coronary artery possesses a smooth muscle relaxant serotonin (5-HT) receptor distinct from previously characterized 5-HT receptors. On the basis of the ability of LY53857 to block weakly coronary smooth muscle relaxation to 5-HT, we examin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::89044e880be11ecb6e77339b5bdc164c
https://pubmed.ncbi.nlm.nih.gov/8667223
https://pubmed.ncbi.nlm.nih.gov/8667223
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 272(1)
The rat gastric fundus is known to possess an "atypical" beta-adrenergic receptor that mediates relaxation to isoproterenol. The purpose of this study was to characterize the relationship between this "atypical" beta receptor in the rat stomach and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::af6620f8858400ca613003e7b01e8edf
https://pubmed.ncbi.nlm.nih.gov/7815362
https://pubmed.ncbi.nlm.nih.gov/7815362
Autor:
Joseph T. MacAndrew, H A Johnson, Michael L. Mangiapane, D J Cushing, S S Ellery, A. L. Rauch, Delvin R. Knight, K. W. Hoover, R A Buchholz, William P. Magee
Publikováno v:
Hypertension (Dallas, Tex. : 1979). 23(6 Pt 2)
A chymase (also referred to as angiotensin I-convertase) specific for the conversion of angiotensin (Ang) I to Ang II has been identified in human heart. This serine protease is also present in dog and marmoset vasculature. We examined the vasoconstr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7822a51596c4c696f398bb1cacba986
https://pubmed.ncbi.nlm.nih.gov/8206618
https://pubmed.ncbi.nlm.nih.gov/8206618
Autor:
D J, Cushing, M L, Cohen
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 264(1)
Serotonin-induced contraction in porcine coronary artery was studied in ring segments of coronary artery without endothelium. 5-hydroxytryptamine (5-HT), 5-methoxytryptamine (5-MeOT) and alpha-methyl-5-HT (alpha Me-5-HT) concentration-dependently con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2200a37a652c1f1b34c7aca348a13753
https://pubmed.ncbi.nlm.nih.gov/8423526
https://pubmed.ncbi.nlm.nih.gov/8423526
Autor:
D J, Cushing, M L, Cohen
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 263(1)
Serotonin (5-HT) is a potent contractile agonist in canine coronary artery devoid of endothelium; however, in higher concentrations 5-HT produces concentration-dependent relaxation by activating an as yet uncharacterized receptor. This study explored
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::856062be76f3f588d4696886269a3257
https://pubmed.ncbi.nlm.nih.gov/1403777
https://pubmed.ncbi.nlm.nih.gov/1403777
Autor:
D J, Cushing, M L, Cohen
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 261(3)
Serotonin (5-HT) is one important mediator of the coronary vasospasm and occlusion associated with thrombosis and atherosclerosis. 5-HT concentration-dependently contracted both canine and porcine coronary artery rings in vitro. In the dog, 5-HT-indu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cfb4c8edce5c6743d70481610c00d012
https://pubmed.ncbi.nlm.nih.gov/1602389
https://pubmed.ncbi.nlm.nih.gov/1602389